Home Alzheimer’s Disease Prioritizing AEs May Lead to Improvement in Communication Between Patients With CLL...

Prioritizing AEs May Lead to Improvement in Communication Between Patients With CLL and Their Oncologists

Focusing the discussion on the risks of adverse events (AEs) with patient goals in mind has the potential to improve communication between oncologists and their patients who are in first-line treatment for chronic lymphocytic leukemia (CLL), according to research published in Patient Preference and Adherence.

The investigators worked to understand further how variations in attributes impact treatment choices between oncologists and patients, as research in this area is very limited.

“These data suggest that patients and oncologists may perceive the risks and benefits associated with novel agents differently,” wrote the investigators. “Patient–oncologist communication could be enhanced through a discussion of the risks of AEs, relative to treatment outcomes, with a focus on available novel therapies.”

The greatest impact on first-line treatment preferences was observed when…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...

Recent Comments